Treatment with FLT3 L/poly I:C, which induces the activation of CD103+ cDC1s at tumour sites and induce proliferation of naïve CD8 T cells and generated CTLs, has been shown to enhance antitumour responses [42–44]. The gene discussed is FLT3; the disease is neoplasm.